Friday, 06 Dec 2019

You are here

Predictors of Serious Infections with Rituximab

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk.

A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum immunoglobulins (at baseline and 4–6 months after each cycle), clinical outcomes and SIE over time.

The patient population included rheumatoid arthritis (72%), systemic lupus erythematosus (13%),  ANCA‐associated vasculitis (7%) and 8% with other RMDs.

The overall SIE rate was 9.8/100 PY - 281 SIEs in 176 patients. Predictors of SIEs included:

  • non‐RTX‐specific comorbidities: prior history of SIE, cancer, chronic lung disease, diabetes, heart failure
  • higher corticosteroid doses
  • RTX‐specific factors;
    • low IgG(<6g/L) at baseline and subsequently
    • RTX‐associated neutropaenia
    • higher IgM
    • longer time‐to‐RTX retreatment

B‐cell depletion numbers were not predictive.

SIEs rates were even higher in those with low baseline IgG (16.4/100 PY) or acquired it during/post‐RTX (21.3/100 PY) when compared to those with normal IgG (9.7/100 PY). 

Monitoring B cell numbers does not appear to be as effective as monitoring serum IgG levels and neutrophils counts in patients who will receive long term or repeated RTX therapy.

Careful patient selection - those with no prior SIE and without comorbidities - may further limit the risk of SIE in such patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

BMS and Celgene Merge as Amgen Buys Otezla

Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.

ACR 2019 – Best of the Plenary Sessions

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.